146 related articles for article (PubMed ID: 16232003)
1. Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization.
Landsman PB; Yu W; Liu X; Teutsch SM; Berger ML
Am J Manag Care; 2005 Oct; 11(10):621-8. PubMed ID: 16232003
[TBL] [Abstract][Full Text] [Related]
2. The effect of incentive-based formularies on prescription-drug utilization and spending.
Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Frank RG
N Engl J Med; 2003 Dec; 349(23):2224-32. PubMed ID: 14657430
[TBL] [Abstract][Full Text] [Related]
3. Three-tiered-copayment drug coverage and use of nonsteroidal anti-inflammatory drugs.
Briesacher B; Kamal-Bahl S; Hochberg M; Orwig D; Kahler KH
Arch Intern Med; 2004 Aug 9-23; 164(15):1679-84. PubMed ID: 15302639
[TBL] [Abstract][Full Text] [Related]
4. A comparison of mail-service and retail community pharmacy claims in 5 prescription benefit plans.
Clark BE; Siracuse MV; Garis RI
Res Social Adm Pharm; 2009 Jun; 5(2):133-42. PubMed ID: 19524861
[TBL] [Abstract][Full Text] [Related]
5. Effect on drug utilization and expenditures of a cost-share change from copayment to coinsurance.
Klepser DG; Huether JR; Handke LJ; Williams CE
J Manag Care Pharm; 2007; 13(9):765-77. PubMed ID: 18062728
[TBL] [Abstract][Full Text] [Related]
6. Effect of tiered prescription copayments on the use of preferred brand medications.
Rector TS; Finch MD; Danzon PM; Pauly MV; Manda BS
Med Care; 2003 Mar; 41(3):398-406. PubMed ID: 12618643
[TBL] [Abstract][Full Text] [Related]
7. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions.
Shrank WH; Hoang T; Ettner SL; Glassman PA; Nair K; DeLapp D; Dirstine J; Avorn J; Asch SM
Arch Intern Med; 2006 Feb; 166(3):332-7. PubMed ID: 16476874
[TBL] [Abstract][Full Text] [Related]
8. Relationship of the use and costs of physician office visits and prescription drugs to travel distance and increases in member cost share.
Cecil WT; Barnes J; Shea T; Coulter SL
J Manag Care Pharm; 2006 Oct; 12(8):665-76. PubMed ID: 17269845
[TBL] [Abstract][Full Text] [Related]
9. The effects of copayments and generic substitution on the use and costs of prescription drugs.
Smith DG
Inquiry; 1993; 30(2):189-98. PubMed ID: 8314607
[TBL] [Abstract][Full Text] [Related]
10. Lowering copayments: impact of simvastatin patent expiration on patient adherence.
Sedjo RL; Cox ER
Am J Manag Care; 2008 Dec; 14(12):813-8. PubMed ID: 19067498
[TBL] [Abstract][Full Text] [Related]
11. Controlling prescription drug expenditures: a report of success.
Miller DP; Furberg CD; Small RH; Millman FM; Ambrosius WT; Harshbarger JS; Ohl CA
Am J Manag Care; 2007 Aug; 13(8):473-80. PubMed ID: 17685828
[TBL] [Abstract][Full Text] [Related]
12. Impact of a Medicaid copayment policy on prescription drug and health services utilization in a fee-for-service Medicaid population.
Hartung DM; Carlson MJ; Kraemer DF; Haxby DG; Ketchum KL; Greenlick MR
Med Care; 2008 Jun; 46(6):565-72. PubMed ID: 18520310
[TBL] [Abstract][Full Text] [Related]
13. Incentive formularies and changes in prescription drug spending.
Landon BE; Rosenthal MB; Normand SL; Spettell C; Lessler A; Underwood HR; Newhouse JP
Am J Manag Care; 2007 Jun; 13(6 Pt 2):360-9. PubMed ID: 17567237
[TBL] [Abstract][Full Text] [Related]
14. Consumer attitudes and factors related to prescription switching decisions in multitier copayment drug benefit plans.
Ganther-Urmie JM; Nair KV; Valuck R; McCollum M; Lewis SJ; Turpin RS
Am J Manag Care; 2004 Mar; 10(3):201-8. PubMed ID: 15032257
[TBL] [Abstract][Full Text] [Related]
15. Managing prescription drug costs.
Sica JM
Empl Benefits J; 2001 Mar; 26(1):35-40. PubMed ID: 11272515
[TBL] [Abstract][Full Text] [Related]
16. The association of consumer cost-sharing and direct-to-consumer advertising with prescription drug use.
Hansen RA; Schommer JC; Cline RR; Hadsall RS; Schondelmeyer SW; Nyman JA
Res Social Adm Pharm; 2005 Jun; 1(2):139-57. PubMed ID: 17138472
[TBL] [Abstract][Full Text] [Related]
17. Impact of patient and plan design factors on switching to preferred statin therapy.
Cox ER; Kulkarni A; Henderson R
Ann Pharmacother; 2007 Dec; 41(12):1946-53. PubMed ID: 17971409
[TBL] [Abstract][Full Text] [Related]
18. Relationship between generic and preferred-brand prescription copayment differentials and generic fill rate.
Mager DE; Cox ER
Am J Manag Care; 2007 Jun; 13(6 Pt 2):347-52. PubMed ID: 17567235
[TBL] [Abstract][Full Text] [Related]
19. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children.
Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Muriel AC; Frank RG
Arch Gen Psychiatry; 2005 Apr; 62(4):435-41. PubMed ID: 15809411
[TBL] [Abstract][Full Text] [Related]
20. Effective strategies for managing pharmacy benefits.
Jacobson D
Healthc Financ Manage; 2001 Mar; 55(3):41-2. PubMed ID: 11258270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]